Masimo (MASI)
(Delayed Data from NSDQ)
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
Here's Why You Should Hold on to Abiomed (ABMD) for Now
by Zacks Equity Research
Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.
Here's Why You Should Invest in Veeva (VEEV) Stock Right Now
by Zacks Equity Research
Strong fundamentals and a solid Q2 aid Veeva (VEEV).
Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost
by Zacks Equity Research
Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.
Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit
by Zacks Equity Research
Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.
New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.
Wright Medical Buys Cartiva to Boost Lower Extremities Unit
by Zacks Equity Research
Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Omnicell Patient Engagement Unit to Aid Medication Adherence
by Zacks Equity Research
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
Tap the Sleep Apnea Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the sleep apnea devices market for grand returns.
Hill-Rom (HRC) Touches 52-Week High: What's Driving It?
by Zacks Equity Research
Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains on strategic partnerships and international prospects.
Ecolab's New Aquanomic Enhances Laundry Operations at Hotels
by Zacks Equity Research
Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.
Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC
by Zacks Equity Research
Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Wright Medical Strong Overseas, Back Order Issues Persist
by Zacks Equity Research
Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.